Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kirindo to Boost Consolidated Sales to \67.5 Bil. in FY2004
May 27, 2002
- Approval No Longer Required for Pseudoephedrine HCl, Sulfate
May 27, 2002
- Cawachi: Ordinary Profits Up 34% to \9 Bil.
May 27, 2002
- Dissolution Tests Proposed for 15 Active Ingredients
May 27, 2002
- Greencross-coa: Strong Growth in Operating, Ordinary Profits
May 27, 2002
- Korosho to Issue Notification to Promote Use of Generics
May 27, 2002
- White Paper Calls for Improved Environment for Small, Medium-sized Firms
May 27, 2002
- Kenporen Calls for Steady Healthcare Reform
May 27, 2002
- Shiseido: Domestic Sales Down for Both Cosmetics, Toiletries
May 27, 2002
- Pharmacies Employ Largest Number of Pharma Graduates
May 27, 2002
- Household Healthcare Costs Up 3.2%
May 27, 2002
- BMS: 1st Qtr Sales Down 7.0% to US$4.3 Bil.
May 27, 2002
- 12-hour Night Shift Work for Nurses Increasing: JNA Survey
May 27, 2002
- Eiken: Sales Up 2.5% to \21.3 Bil., Net Profits Up 44.4% to \1.2 Bil.
May 27, 2002
- Neoral Reduces Kidney Rejection Rates: MO2ART Study
May 27, 2002
- Worker Consultation Service Receives 5,398 Calls: LWC Survey
May 27, 2002
- Kainos: Automatic ELISA System for Microplates
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （1）
May 27, 2002
- Improvement of Nurse Training Recommended
May 27, 2002
- WEBSITE NEWS
May 27, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…